Semaglutide vs. Tirzepatide vs. Retatrutide: What’s the Difference?
Share
If you’ve been hearing about weight loss solutions like Ozempic®, Mounjaro™, or the newer Retatrutide, you’re not alone. These compounds—Semaglutide, Tirzepatide, and Retatrutide—are gaining attention for their powerful effects in research settings focused on weight management.
Although they may seem similar, each one works a bit differently. In this article, we’ll break down what makes each compound unique, how they support fat loss, and what to consider when comparing them.
What is Semaglutide?
Also known as: Ozempic®, Wegovy®
Mechanism: GLP-1 receptor agonist
Semaglutide helps regulate hunger by mimicking a natural hormone (GLP-1) in the body. This slows digestion and helps create a feeling of fullness—making it easier to reduce calorie intake.
- Up to 15% body weight reduction over time
- Weekly injection protocols
- Popular for those beginning weight-related research
What is Tirzepatide?
Also known as: Mounjaro™, Zepbound™
Mechanism: Dual agonist (GLP-1 + GIP)
Tirzepatide works on two hormone pathways (GLP-1 and GIP), giving it a stronger appetite-suppressing and insulin-regulating effect compared to Semaglutide. This can lead to greater fat loss.
- Up to 20% average body weight reduction
- Once-weekly injection schedule
- Ideal for more aggressive or advanced weight loss studies
What is Retatrutide?
Status: Currently in clinical trials
Mechanism: Triple agonist (GLP-1 + GIP + Glucagon)
Retatrutide is the newest compound being studied. It targets three key hormone pathways, potentially making it the most powerful of the three. While not yet available for commercial use, early data is promising.
- Up to 24% body weight reduction in under a year
- Triple-pathway targeting for appetite, fat breakdown, and energy balance
- A potential breakthrough for future research
Quick Comparison Chart
| Compound | Pathways Targeted | Avg. Weight Reduction | Frequency | Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | Weekly | Widely available |
| Tirzepatide | GLP-1 + GIP | ~20% | Weekly | Approved & popular |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% (early trials) | Weekly | In clinical trials |
Which Compound Is Right for Your Research?
- New to peptides? Semaglutide is a well-studied starting point.
- Looking for stronger results? Tirzepatide may offer enhanced outcomes.
- Interested in cutting-edge research? Retatrutide is the one to watch.
Note: All compounds are for research use only. They are not for human consumption or clinical use.
Explore Research Compounds
Browse our available inventory of Semaglutide, Tirzepatide, and other compounds below: